None listed
Conditions
Interventions
Intervention1: Emblica Officinalis Capsules: Dose : 250 mg capsule
Route of administration : oral
Treatment Duration : 14 Days
Subject was asked to take 2 capsules twice daily with 240 ml of water
Con
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1.Participants of either gender between 18-45 years of age and BMI of 18.5 to 2.Participants willing to sign informed consent 3.Participants with normal healthy conditions- Normal vitals, Physical examination, Normal weight and height as per LIC chart
Exclusion criteria
Exclusion criteria: 1.H/o of drug dependence or any severe co-morbid medical conditions. 2.H/o of serious adverse reactions or hypersensitivity to any drug. 3.Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study. 4.Abnormality in routine lab investigations like complete blood picture, complete urine examination, liver function tests or renal function tests. 5.Participating in any drug trials/ research projects over the past 3 months. 6.Alcohol consumption 24 hrs before study day. 7.Tea/Coffee consumption or smoking 12 hrs before the study day.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in Cardiovascular Parameters like Aortic Pressure, Augmentation Index,Blood PresureTimepoint: Baseline and Post Treatment-Day 15 | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety and Tolerability of Emblica officinalisTimepoint: Baseline and Post Treatment-Day 15 | — |
Countries
India
Contacts
Public ContactDr Usharani
Nizams Institute of Medical Sciences
Outcome results
None listed